


Copper-Catalyzed Three Component Regio- and Stereospecific Selenosulfonation of Alkynes: Synthesis of (*E*)- β -Selenovinyl Sulfones

Yang Liu, Guangfan Zheng, Qian Zhang,[†] Yan Li,^{*†} and Qian Zhang^{*†}

Key Laboratory of Functional Organic Molecule Design & Synthesis of Jilin Province, Department of Chemistry, Northeast Normal University, 5268 Renmin Street, Changchun, Jilin 130024, China

S Supporting Information

ABSTRACT: A copper-catalyzed highly regio- and stereospecific selenosulfonation of alkynes with arylsulfonohydrazides and diphenyl diselenide has been developed. This novel three component reaction proceeds under very mild conditions and with a broad scope of substrates, providing a wide range of (*E*)- β -selenovinyl sulfones in good to excellent yields.




Vinyl sulfones are unique motifs in some biologically active molecules¹ and usefully synthetic intermediates in organic synthesis.² Accordingly, considerable effort has been devoted to develop new and efficient methods for the construction of these compounds,³ including the oxidation of the corresponding vinyl sulides,⁴ Knoevenagel condensation of aromatic aldehydes with sulfonylacetic acids,⁵ Wittig reaction of α -sulfonyl phosphonium ylides,⁶ β -elimination of selenosulfones or halosulfones,⁷ and sulfonation of alkenes⁸/alkynes.^{9–12} Among them, sulfonative functionalization of alkynes, the addition of sulfonyl and other groups across a triple bond, represents one of the most straightforward strategies. For example, alkynes sulfonative difunctionalization, such as halosulfonylation,⁹ sulfonyloxidation,¹⁰ sulfonamination,¹¹ and sulfonylcarbonation,¹² has been successfully realized for the synthesis of various sulfonative difunctionalization products. Vinyl selenides¹³ are useful synthetic intermediates and therapeutic entities that display a wide spectrum of biological activities, thus rendering these motifs highly important synthetic targets.¹⁴ β -Selenovinyl sulfones could be obtained through radical selenosulfonation of alkynes and Se-phenyl *p*-tolueneselenosulfonate (Scheme 1a),¹⁵ which usually need to be prepared through the reaction of sulfinates, sulfonohydrazides, or selenenyl halides with benzeneseleninic acid, or sodium sulfinates with diphenyl diselenide.¹⁶ Therefore, the development of direct three component selenosulfonation reactions starting from readily

available sulfonyl and selenyl radical sources is highly desirable. In this context, Huang and co-workers realized selenosulfonation of acetylenes with sodium arenesulfonates and diphenyl diselenide (Scheme 1b).¹⁷ However, these reactions were performed at 80 °C and only terminal alkynes were viable substrates. Recently, we realized copper-catalyzed radical aminative functionalizations of alkynes.¹⁸ As our continuous interest in radical reactions,¹⁹ we expected to explore three component radical selenosulfonation of alkynes. Herein, we reported a novel copper-catalyzed regio- and stereospecific selenosulfonation of alkynes with arylsulfonohydrazides and diphenyl diselenide under very mild conditions, synthesizing a wide range of (*E*)- β -selenovinyl sulfones (Scheme 1b).


Initially, the reaction of prop-1-yn-1-ylbenzene (**1a**, 0.3 mmol) with *p*-toluenesulfonyl hydrazide (**2a**, 1.2 equiv) and diphenyl diselenide (**3**, 0.5 equiv) was chosen as model reaction to optimize the conditions. No reaction occurred at 70 °C in CH₃CN without catalyst and oxidant (Table 1, entry 1). In the presence of K₂S₂O₈ (2 equiv), to our delight, the desired selenosulfonation product **4a** was obtained in 43% yield (Table 1, entry 2). Upon adding Cu(MeCN)₄PF₆ (5 mol %), 72% of **4a** was obtained (Table 1, entry 3). When the temperature was decreased to 50 °C, a better yield (92%) of **4a** was given (Table 1, entry 4). Among CH₃CN, DCE, CH₃OH, DMF, THF, and toluene, CH₃CN was the best solvent (Table 1, entries 4–9). Other oxidants, such as H₂O₂, DTBP, and TBHP, were also examined, but the result was not improved (Table 1, entries 10–12). Other copper-catalysts such as CuBr·Me₂S, CuBr, CuCl, CuI, and Cu(OAc)₂ were not as efficient as Cu(MeCN)₄PF₆ (Table 1, entries 13–17). Finally, we tried to conduct the reaction at room temperature. Satisfactorily, the yield of **4a** was improved to 98% (Table 1, entry 18), while, in the absence of the catalyst, no reaction was observed (Table 1, entry 19). The configuration of **4a** was further confirmed by X-ray analysis.²⁰

Scheme 1. Selenosulfonation of Alkynes

(a) two component reaction:



(b) three component reaction:




this work:



Received: December 21, 2016

Published: January 26, 2017


Table 1. Optimization of Reaction Conditions^a


entry	catalyst	oxidant	solvent	T (°C)	yield ^b (%)
1	none	none	CH ₃ CN	70	0
2	none	K ₂ S ₂ O ₈	CH ₃ CN	70	43
3	Cu(MeCN) ₄ PF ₆	K ₂ S ₂ O ₈	CH ₃ CN	70	72
4	Cu(MeCN) ₄ PF ₆	K ₂ S ₂ O ₈	CH ₃ CN	50	92
5	Cu(MeCN) ₄ PF ₆	K ₂ S ₂ O ₈	DCE	50	68
6	Cu(MeCN) ₄ PF ₆	K ₂ S ₂ O ₈	CH ₃ OH	50	35
7	Cu(MeCN) ₄ PF ₆	K ₂ S ₂ O ₈	DMF	50	27
8	Cu(MeCN) ₄ PF ₆	K ₂ S ₂ O ₈	THF	50	50
9	Cu(MeCN) ₄ PF ₆	K ₂ S ₂ O ₈	toluene	50	43
10	Cu(MeCN) ₄ PF ₆	H ₂ O ₂	CH ₃ CN	50	40
11	Cu(MeCN) ₄ PF ₆	DTBP	CH ₃ CN	50	0
12	Cu(MeCN) ₄ PF ₆	TBHP	CH ₃ CN	50	70
13	CuBr·Me ₂ S	K ₂ S ₂ O ₈	CH ₃ CN	50	75
14	CuBr	K ₂ S ₂ O ₈	CH ₃ CN	50	68
15	CuCl	K ₂ S ₂ O ₈	CH ₃ CN	50	78
16	CuI	K ₂ S ₂ O ₈	CH ₃ CN	50	45
17	Cu(OAc) ₂	K ₂ S ₂ O ₈	CH ₃ CN	50	65
18	Cu(MeCN) ₄ PF ₆	K ₂ S ₂ O ₈	CH ₃ CN	rt	98
19	none	K ₂ S ₂ O ₈	CH ₃ CN	rt	0

^aGeneral reaction conditions: **1a** (0.3 mmol), **2a** (0.36 mmol), **3** (0.15 mmol), catalyst (5 mol %), oxidant (0.6 mmol), solvent (2 mL), nitrogen atmosphere, 12 h. Ts = -SO₂C₆H₄-*p*-CH₃. ^bIsolated yield.

With the optimized reaction conditions (Table 1, entry 18), we next explored the scope of the selenosulfonation process with respect to internal alkynes **1** and arylsulfonylhydrazides **2**; the results are shown in Table 2. Delightfully, the internal alkynes with alkyl (**1a–e**) or aryl (**1e**) smoothly participated in this highly regio- and stereoselective selenosulfonation reaction to provide (*E*)- β -selenovinyl sulfones **4a–e** in moderate to excellent yields. It should be noted that a synthetically attractive hydroxyl group, which is sensitive to oxidants survived from the reaction conditions, gave the expected product **4d** in an accepted yield (53%). The substrates **1f–m**, bearing either electron-donating or electron-withdrawing groups on the benzene ring, were compatible with this reaction as well, affording desired (*E*)- β -selenovinyl sulfones **4f–m** in 53–88% yields. In addition, internal aliphatic alkyne **1n** successfully underwent selenosulfonation to give **4n**, albeit in a low yield. Next, the scope of arylsulfonylhydrazides **2** was examined. Gratifyingly, introduction of methoxyl, methyl, and halogen groups into the aromatic ring of sulfonylhydrazides was well-tolerated, and the corresponding (*E*)- β -selenovinyl sulfones **4o–q** were formed in good to excellent yield. It should be noted that, in all reactions, no other isomers were observed.

Inspired by the above excellent results, we set out to explore the selenosulfonation of terminal alkynes. As described in Table 3, aromatic terminal alkynes with a wide range of functional groups, such as F, Cl, Br, CN, NO₂, MeOCO, Me, Et, and *t*-Bu, were well tolerated, producing (*E*)- β -selenovinyl sulfones **6a–m** in up to 95% yield. Gratifyingly, aliphatic alkynes **5n** and **5o** were viable substrates for the selenosulfonation, producing **6n** and **6o** with a yield of 82% and 85%, respectively. Significantly, aliphatic alkynes with Cl (**5p**), OH (**5q**), and TMS (**5r**) groups


Table 2. Scope of Internal Alkynes and Arylsulfonylhydrazides^a

^aReaction conditions: **1** (0.3 mmol), **2** (0.36 mmol), **3** (0.15 mmol), Cu(MeCN)₄PF₆ (5 mol %), K₂S₂O₈ (0.6 mmol), CH₃CN (2 mL), nitrogen atmosphere, room temperature, 12 h. Isolated yield. Ts = -SO₂C₆H₄-*p*-CH₃.

which can readily undergo further transformation were found to be suitable for the reaction, delivering the desired (*E*)- β -selenovinyl sulfones **6p–r**. The configurations of **6a** and **6p** were further confirmed by X-ray analysis.²⁰ Additionally, dimethyl diselenide was efficient for this reaction, providing the corresponding selenosulfonation product **6s** in 35% yield.


In order to demonstrate the synthetic utility of the three component selenosulfonation of alkynes with aryl sulfonylhydrazides and diphenyl diselenide, we performed this three component reaction on a gram scale (Scheme 2). Pleasingly, 3.93 g of (*E*)- β -selenovinyl sulfone **4a** was isolated.

To gain some insights into the reaction mechanism, some control experiments were carried out. As known, selenosulfonates might be formed from the reaction of arylsulfonylhydrazides with diphenyl diselenide. Thus, the reaction of prop-1-yn-1-ylbenzene (**1a**) with Se-phenyl *p*-tolueneselenosulfonate was performed under optimized conditions (Table 1, entry 18). No reaction occurred, and the substrate was recovered completely. This result showed that the selenosulfonation might not involve a selenosulfonate intermediate. Next, when 1 equiv of BHT and 1 equiv of TEMPO were added to the reaction of **1a** under standard conditions, the yield of **4a** decreased to 17% and 21%, respectively. With 2 equiv of BHT and 2 equiv of TEMPO, the selenosulfonation was completely

Table 3. Variety of Terminal Alkynes and Diselenides^a

^aReaction conditions: **5** (0.3 mmol), **2a** (0.36 mmol), **3** (0.15 mmol), Cu(MeCN)₄PF₆ (5 mol %), K₂S₂O₈ (0.6 mmol), CH₃CN (2 mL), nitrogen atmosphere, room temperature, 12 h. Isolated yield. Ts = -SO₂C₆H₄-*p*-CH₃.


Scheme 2. Gram-Scale Synthesis of (*E*)-β-Selenovinyl Sulfone



suppressed and no **4a** was detected. These results suggested that this transformation might proceed via a radical pathway.

On the basis of the experimental results and literatures,^{7b,15a,b,21} a proposed radical mechanism is shown in Scheme 3. Initially, the sulfonyl radical **A** was generated in the presence of copper salt and K₂S₂O₈ via a single electron transfer and deprotonation process, along with the release of N₂.²² Then, the sulfonyl radical **A** regioselectively added to alkynes, forming a relatively stable β-sulfonyl vinyl radical **B**. Subsequently, the phenyl selenol group transferred from

Scheme 3. Proposed Mechanism



diphenyl diselenide to **B** or coupled between **B** and phenyl selenol radical to afford thermodynamically stable (*E*)-β-selenovinyl sulfone **4a**. Alternatively, the phenyl selenol group transfer might be much more rapid than the inversion of **B**,^{15b} thus resulting in a single isomer **4a**.

In conclusion, we have developed a copper-catalyzed highly regio- and stereospecific selenosulfonation of alkynes with aryl sulfonylhydrazides and diphenyl diselenide. This three component reaction proceeds under very mild conditions and with a broad scope of substrates. With the reaction, a wide range of (*E*)-β-selenovinyl sulfones are synthesized in good to excellent yields.

EXPERIMENTAL SECTION

General Experimental Methods. All the reagents were used as purchased from commercial suppliers without further purification. Acetonitrile was distilled over calcium hydride before use. Analytical thin layer chromatography (TLC) was performed on precoated alumina-backed silica gel plates (0.2 mm thickness) which were developed using UV fluorescence. Flash chromatography was performed on silica gel (300–400 mesh). Melting points were measured on a standard melting point apparatus and are uncorrected. ¹H NMR spectra were recorded on a 400, 500, or 600 MHz spectrometer, while ¹³C NMR spectra were recorded on a 100, 125, and 150 MHz instrument. Chemical shifts are reported in δ ppm referenced to an internal TMS standard for ¹H NMR and chloroform-*d* (δ = 77.0 ppm) for ¹³C NMR. HRMS spectra were recorded using FAB (TOF analyzer) or ESI (TOF analyzer). Single-crystal X-ray diffraction data were recorded at a temperature of 293(2) K on an Oxford Diffraction Gemini R Ultra diffractometer, using a ω scan technique with Mo-*K*α radiation (λ = 0.71073 Å).

Characterization Data for Selenosulfonation Products. **4a**, **4e**, and **6a** were reported by Miura and co-workers.^{15a} **4n**, **6a**, **6d**, and **6j** were reported by Back and co-workers.^{15b} **4b–4d**, **4f–4m**, **4o–4q**, **6b**, **6c**, **6e–6i**, and **6k–6r** were synthesized as follows.

General Procedure A for the Synthesis of Products **4** and **6**.

In a dried glass vial, equipped with a magnetic stir bar, charged with PhSeSePh (46.8 mg, 0.15 mmol, 0.5 equiv), Cu(MeCN)₄PF₆ (5.6 mg, 5 mol %), and K₂S₂O₈ (162.2 mg, 0.6 mmol, 2.0 equiv) under a nitrogen atmosphere, 2 mL of MeCN was added next, followed by addition of alkyne **1** or **5** (0.3 mmol, 1.0 equiv) and benzenesulfonyl hydrazide (0.36 mmol, 1.2 equiv). After stirring for 12 h, the reaction mixture was concentrated; then the residue was subjected to column chromatography on silica gel (petroleum ether:diethyl ether = 40:1–12:1) to afford the desired product **4** or **6**.

(*E*)-Phenyl(1-phenyl-2-tosylprop-1-en-1-yl)selane (4a**).**^{15a} Following the general procedure A, **4a** was obtained as a white solid (98% yield, 125.8 mg). mp: 93–94 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.37 (d, *J* = 8.5 Hz, 2H), 7.18–7.06 (m, 5H), 7.02–6.86 (m, 5H), 6.74–6.68 (m, 2H), 2.38 (s, 3H), 2.36 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 151.0, 143.4, 138.3, 137.0, 135.9, 129.2, 129.1, 128.6, 128.5, 127.7, 127.3, 127.0, 126.7, 21.5, 18.7. HRMS (ESI-TOF) (*m/z*): Calcd for C₂₂H₂₀O₂SSe ([M + H]⁺), 429.0427, found 429.0422.

(*E*)-Phenyl(1-phenyl-2-tosylpent-1-en-1-yl)selane (4b**).** Following the general procedure A, **4b** was obtained as a white solid (93% yield, 127.2 mg). mp: 102–104 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.21 (d, *J* = 8.4 Hz, 2H), 7.12–7.04 (m, 3H), 7.01 (d, *J* = 8.0 Hz, 2H), 6.98–6.85 (m, 3H), 6.80 (t, *J* = 7.6 Hz, 2H), 6.65–6.54 (m, 2H), 2.96–2.82

(m, 2H), 2.32 (s, 3H), 1.95–1.78 (m, 2H), 1.13 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 150.9, 143.0, 139.2, 138.6, 136.9, 129.3, 128.9, 128.5, 128.3, 127.4, 127.1, 126.8, 126.5, 35.2, 22.4, 21.4, 14.1. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{24}\text{H}_{24}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 479.0566, found 479.0567.

(*E*)-(3-Methoxy-1-phenyl-2-tosylprop-1-en-1-yl)(phenyl)selane (**4c**). Following the general procedure A, **4c** was obtained as a yellow oil. (93% yield, 127.8 mg). ^1H NMR (400 MHz, CDCl_3) δ 7.28 (d, $J = 8.4$ Hz, 2H), 7.17–7.00 (m, 5H), 6.98–6.89 (m, 3H), 6.85 (t, $J = 8.0$ Hz, 2H), 6.66 (d, $J = 7.2$ Hz, 2H), 4.70 (s, 2H), 3.47 (s, 3H), 2.33 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 160.1, 143.2, 138.6, 136.8, 135.4, 135.3, 129.00, 128.96, 128.6, 128.4, 127.6, 127.2, 126.6, 70.0, 58.0, 21.4. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{23}\text{H}_{22}\text{O}_3\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 481.0368, found 481.0359.

(*E*)-1,3-Diphenyl-3-(phenylselanyl)-2-tosylprop-2-en-1-ol (**4d**). Following the general procedure A, **4d** was obtained as a white solid. (53% yield, 82.7 mg). mp: 170–171 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, $J = 8.0$ Hz, 2H), 7.48 (t, $J = 7.2$ Hz, 2H), 7.38 (t, $J = 7.6$ Hz, 1H), 7.14–7.05 (m, 3H), 7.00–6.81 (m, 8H), 6.75 (dd, $J = 19.2, 7.2$ Hz, 2H), 6.51 (d, $J = 10.8$ Hz, 2H), 4.71 (d, $J = 11.2$ Hz, 1H), 2.29 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.8, 143.4, 141.0, 140.7, 138.6, 137.0, 134.9, 129.8, 129.4, 128.9, 128.8, 128.6, 127.65, 127.63, 127.61, 126.82, 126.78, 126.6, 75.4, 21.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{28}\text{H}_{24}\text{O}_3\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 543.0511, found 543.0515.

(*E*)-(1,2-Diphenyl-2-tosylvinyl)(phenyl)selane (**4e**).^{15a} Following the general procedure A, **4e** was obtained as a white solid. (42% yield, 61.7 mg). mp: 167–168 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.46–7.40 (m, 3H), 7.38–7.34 (m, 2H), 7.27–7.22 (m, 2H), 7.10–7.03 (m, 5H), 7.03–6.99 (m, 3H), 6.94–6.89 (m, 4H), 2.35 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 154.8, 143.5, 138.0, 137.4, 137.1, 135.2, 134.7, 131.0, 129.3, 128.8, 128.5, 128.3, 127.7, 127.5, 126.9, 21.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{27}\text{H}_{22}\text{O}_2\text{SSe}$ ($[\text{M} + \text{H}]^+$), 491.0589, found 491.0586.

(*E*)-(1-(3,4-Dimethylphenyl)-2-tosylpent-1-en-1-yl)(phenyl)selane (**4f**). Following the general procedure A, **4f** was obtained as a white solid. (79% yield, 114.7 mg). mp: 89–90 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.20 (d, $J = 8.4$ Hz, 2H), 7.10–7.04 (m, 3H), 7.03–6.89 (m, 4H), 6.64 (d, $J = 7.6$ Hz, 1H), 6.49 (dd, $J = 8.0, 1.6$ Hz, 1H), 6.06 (s, 1H), 2.84–2.95 (m, 2H), 2.33 (s, 3H), 2.03 (s, 3H), 1.82 (m, 6H), 1.61–1.46 (m, 2H), 1.04 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 150.9, 142.7, 139.3, 138.9, 136.9, 135.5, 134.4, 133.1, 130.3, 128.6, 128.3, 128.1, 127.8, 127.6, 127.1, 33.0, 31.1, 22.9, 21.4, 19.3, 19.0, 13.8. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{26}\text{H}_{27}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 506.0795, found 506.0791.

(*E*)-(1-(2-Methoxyphenyl)-2-tosylpent-1-en-1-yl)(phenyl)selane (**4g**). Following the general procedure A, **4g** was obtained as a white solid. (88% yield, 128.3 mg). mp: 99–100 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.20–7.27 (m, 2H), 7.12–7.05 (m, 3H), 6.99 (d, $J = 8.4$ Hz, 2H), 6.96–6.83 (m, 4H), 6.64 (t, $J = 7.6$ Hz, 1H), 5.99 (d, $J = 8.0$ Hz, 1H), 3.19 (s, 3H), 2.81 (q, $J = 4.0$ Hz, 2H), 2.32 (s, 3H), 1.99–1.79 (m, 2H), 1.12 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 154.5, 148.7, 142.6, 138.4, 137.9, 137.3, 131.4, 129.5, 128.5, 127.9, 127.7, 126.6, 124.33, 119.0, 108.9, 54.0, 34.7, 22.0, 21.4, 14.1. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{25}\text{H}_{26}\text{O}_3\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 509.0664, found 507.0661.

(*E*)-(1-(2,4-Difluorophenyl)-2-tosylpent-1-en-1-yl)(phenyl)selane (**4h**). Following the general procedure A, **4h** was obtained as a white solid. (75% yield, 110.7 mg). mp: 96–97 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.39 (d, $J = 8.4$ Hz, 2H), 7.24–7.11 (m, 5H), 7.07–6.97 (m, 2H), 6.76 (td, $J = 8.4, 6.4$ Hz, 1H), 6.58–6.45 (m, 1H), 6.20 (td, $J = 9.6, 2.4$ Hz, 1H), 2.87–2.67 (m, 2H), 2.37 (s, 3H), 1.92–1.70 (m, 2H), 1.09 (t, $J = 7.6$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 162.6 (dd, $J = 298.6, 11.5$ Hz), 157.8 (dd, $J = 298.6, 14.7$ Hz), 143.7, 140.2, 137.8, 137.3, 131.9 (dd, $J = 9.6, 3.9$ Hz), 129.2, 128.6, 127.5, 125.9, 120.4 (dd, $J = 19.1, 3.6$ Hz), 109.9 (dd, $J = 21.4, 3.3$ Hz), 102.7 (t, $J = 25.5$ Hz), 102.52, 35.0, 21.8, 21.5, 14.1. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{24}\text{H}_{22}\text{F}_2\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 515.0372, found 515.0377.

(*E*)-*N,N*-Diethyl-4-(1-(phenylselanyl)-2-tosylbut-1-en-1-yl)benzamide (**4i**). Following the general procedure A, **4i** was obtained as a

white solid. (66% yield, 109.9 mg). mp: 123–124 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.16 (d, $J = 8.0$ Hz, 2H), 7.13–6.98 (m, 5H), 6.96–6.88 (m, 2H), 6.78–6.71 (m, 2H), 6.59 (d, $J = 8.0$ Hz, 2H), 3.52–3.31 (bs, 2H), 2.97–2.78 (m, 4H), 2.29 (s, 3H), 1.92–1.77 (m, 2H), 1.19–1.01 (m, 6H), 1.02–0.85 (m, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 170.3, 149.4, 143.2, 140.0, 138.3, 137.1, 136.5, 136.0, 129.3, 129.0, 128.5, 128.4, 127.3, 126.7, 124.4, 35.1, 22.3, 21.3, 14.0. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{29}\text{H}_{33}\text{NO}_3\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 578.1249, found 578.1245.

(*E*)-(1-(4-Bromophenyl)-2-tosylpent-1-en-1-yl)(phenyl)selane (**4j**). Following the general procedure A, **4j** was obtained as a white solid. (93% yield, 149.0 mg). mp: 132–133 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.27–7.22 (m, 3H), 7.15 (t, $J = 7.2$ Hz, 1H), 7.08 (t, $J = 8.4$ Hz, 4H), 7.00 (t, $J = 7.8$ Hz, 2H), 6.96–6.90 (m, 2H), 6.47 (d, $J = 8.4$ Hz, 2H), 2.91–2.82 (m, 2H), 2.36 (s, 3H), 1.90–1.77 (m, 2H), 1.11 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 149.0, 143.4, 140.4, 138.5, 137.0, 135.0, 130.9, 129.9, 129.1, 128.7, 127.5, 126.6, 121.5, 35.3, 22.4, 21.5, 14.2. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{24}\text{H}_{23}\text{BrO}_2\text{SSe}$ ($[\text{M} + \text{H}]^+$), 536.9826, found 536.9831.

(*E*)-(1-(Naphthalen-1-yl)-2-tosylpent-1-en-1-yl)(phenyl)selane (**4k**). Following the general procedure A, **4k** was obtained as a white solid. (85% yield, 129.1 mg). mp: 77–78 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.49–7.37 (m, 3H), 7.25–7.18 (m, 2H), 7.04 (t, $J = 6.8$ Hz, 1H), 7.01–6.91 (m, 3H), 6.90–6.83 (m, 1H), 6.81–6.73 (m, 2H), 6.69–6.56 (m, 4H), 3.12–2.91 (m, 2H), 2.13–1.97 (m, 5H), 1.23 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (125 MHz, CDCl_3) δ 149.3, 142.6, 140.2, 137.3, 137.1, 132.4, 132.2, 129.9, 128.5, 128.4, 128.2, 127.6, 127.5, 127.4, 126.0, 125.7, 125.13, 125.11, 123.9, 34.8, 22.3, 21.1, 14.3. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{28}\text{H}_{26}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 529.0716, found 529.0723.

(*E*)-(5-Chloro-1-(*p*-tolyl)-2-tosylpent-1-en-1-yl)(phenyl)selane (**4l**). Following the general procedure A, **4l** was obtained as a white solid. (86% yield, 130.0 mg). mp: 108–109 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.23 (d, $J = 7.8$ Hz, 2H), 7.13–7.05 (m, $J = 14.9, 7.8$ Hz, 3H), 7.03 (d, $J = 8.4$ Hz, 2H), 6.94 (t, $J = 7.8$ Hz, 2H), 6.63 (d, $J = 7.8$ Hz, 2H), 6.49 (d, $J = 8.4$ Hz, 2H), 3.72 (t, $J = 6.6$ Hz, 2H), 3.07–2.98 (m, 2H), 2.37–2.28 (m, 5H), 2.13 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ 152.5, 143.2, 138.4, 137.4, 137.2, 136.9, 132.7, 129.1, 128.9, 128.5, 128.4, 127.5, 127.3, 126.8, 44.6, 31.5, 30.9, 21.4, 21.1. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{26}\text{H}_{27}\text{ClO}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 541.0489, found 541.0485.

(*E*)-(2-Cyclopropyl-1-(*p*-tolyl)-2-tosylvinyl)(phenyl)selane (**4m**). Following the general procedure A, **4m** was obtained as a white solid. (87% yield, 122.2 mg). mp: 105–106 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.46 (d, $J = 8.4$ Hz, 2H), 7.19–7.05 (m, 5H), 6.98 (t, $J = 7.6$ Hz, 2H), 6.77–6.65 (m, 4H), 2.35 (s, 3H), 2.16 (s, 3H), 1.23–1.15 (m, 3H), 1.03–0.94 (m, 2H). ^{13}C NMR (126 MHz, CDCl_3) δ 155.6, 143.0, 138.8, 137.5, 136.3, 133.1, 129.2, 128.9, 128.1, 127.7, 127.5, 21.5, 21.1, 13.6, 10.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{25}\text{H}_{24}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 491.0561, found 491.0569.

(*E*)-Phenyl(4-tosylhex-3-en-3-yl)selane (**4n**).^{15b} Following the general procedure A, **4n** was obtained as a white solid. (47% yield, 55.6 mg). mp: 56–57 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.77 (d, $J = 7.8$ Hz, 2H), 7.55 (d, $J = 7.2$ Hz, 2H), 7.39 (t, $J = 7.8$ Hz, 1H), 7.36–7.29 (m, 4H), 2.74–2.63 (m, 4H), 2.44 (s, 3H), 1.15 (t, $J = 7.8$ Hz, 3H), 0.86 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.7, 143.9, 139.3, 137.5, 136.4, 129.7, 129.4, 129.1, 127.3, 127.0, 27.4, 26.7, 21.6, 14.6, 13.6. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{19}\text{H}_{22}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 417.0408, found 417.0410.

(*E*)-(2-((4-Methoxyphenyl)sulfonyl)-1-phenylprop-1-en-1-yl)(phenyl)selane (**4o**). Following the general procedure A, **4o** was obtained as a white solid. (79% yield, 105.2 mg). mp: 87–88 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.40 (d, $J = 8.8$ Hz, 2H), 7.14–7.08 (m, 3H), 7.03–6.87 (m, 5H), 6.79 (d, $J = 9.2$ Hz, 2H), 6.75–6.68 (m, 2H), 3.81 (s, 3H), 2.38 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 162.9, 150.5, 136.9, 136.0, 132.8, 129.7, 129.1, 128.6, 128.4, 127.3, 126.7, 113.8, 55.5, 18.7. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{22}\text{H}_{20}\text{O}_3\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 467.0197, found 467.0205.

(*E*)-(2-(Mesitylsulfonyl)-1-phenylprop-1-en-1-yl)(phenyl)selane (**4p**). Following the general procedure A, **4p** was obtained as a white

solid. (82% yield, 112.2 mg). mp: 92–93 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.11–7.05 (m, 3H), 6.93 (t, J = 7.8 Hz, 2H), 6.79 (t, J = 7.8 Hz, 1H), 6.70 (t, J = 7.8 Hz, 2H), 6.63 (s, 2H), 6.56 (d, J = 7.2 Hz, 2H), 2.42 (s, 3H), 2.29 (s, 6H), 2.17 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 147.7, 142.0, 139.1, 137.0, 135.6, 135.5, 135.0, 131.5, 128.7, 128.5, 128.4, 127.1, 127.0, 126.6, 21.9, 20.8, 17.8. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{26}\text{H}_{28}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 507.0879, found 507.0871.

(*E*)-(1-(4-Chlorophenyl)sulfonyl)-1-phenylprop-1-en-1-yl-(phenyl)selane (**4q**). Following the general procedure A, **4q** was obtained as a white solid. (75% yield, 100.8 mg). mp: 125–126 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.34 (d, J = 8.4 Hz, 2H), 7.26 (d, J = 2.4 Hz, 1H), 7.11–7.05 (m, 2H), 6.99–6.92 (m, 3H), 6.89 (t, J = 7.2 Hz, 2H), 6.66 (d, J = 7.2 Hz, 2H), 2.42 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 152.1, 139.9, 139.1, 137.0, 135.5, 132.5, 129.2, 129.0, 128.8, 128.7, 128.5, 127.5, 126.9, 18.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{21}\text{H}_{17}\text{ClO}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 470.9705, found 470.9708.

(*E*)-Phenyl(1-phenyl-2-tosylvinyl)selane (**6a**).^{15a,b} Following the general procedure A, **6a** was obtained as a white solid. (95% yield, 118.0 mg). mp: 150–151 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.61–7.55 (m, 2H), 7.46–7.42 (m, 1H), 7.41–7.37 (m, 2H), 7.36–7.23 (m, 5H), 7.21–7.15 (m, 2H), 7.10 (d, J = 8.4 Hz, 2H), 6.16 (s, 1H), 2.36 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 157.1, 143.5, 136.5, 134.6, 130.12, 130.09, 129.24, 129.23, 128.4, 127.8, 127.4, 126.8, 125.8, 21.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{21}\text{H}_{18}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 437.0089, found 437.0100.

(*E*)-(1-(4-Fluorophenyl)-2-tosylprop-1-en-1-yl)(phenyl)selane (**6b**). Following the general procedure A, **6b** was obtained as a white solid. (82% yield, 106.3 mg). mp: 113–115 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.56 (d, J = 6.8 Hz, 2H), 7.48–7.29 (m, 5H), 7.23–7.12 (m, 4H), 6.96 (t, J = 8.8 Hz, 2H), 6.19 (s, 1H), 2.38 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 163.2 (d, J = 248.0), 155.8, 143.7, 138.7, 136.5, 130.59 (d, J = 9.0 Hz), 130.15, (d, J = 5.4 Hz), 129.3, 127.3, 126.7, 126.5, 115.0 (d, J = 22.0), 114.9, 21.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{21}\text{H}_{17}\text{FO}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 454.9998, found 454.9998.

(*E*)-(1-(4-Chlorophenyl)-2-tosylprop-1-en-1-yl)(phenyl)selane (**6c**). Following the general procedure A, **6c** was obtained as a white solid. (92% yield, 123.6 mg). mp: 122–123 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.58–7.52 (m, 2H), 7.46–7.41 (m, 1H), 7.38 (t, J = 7.2 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.25–7.22 (m, 2H), 7.17–7.11 (m, 4H), 6.18 (s, 1H), 2.39 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 155.4, 143.9, 138.7, 136.5, 135.5, 133.1, 130.2, 129.9, 129.4, 128.1, 127.4, 126.5, 21.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{21}\text{H}_{17}\text{ClO}_2\text{SSe}$ ($[\text{M} + \text{H}]^+$), 448.9877, found 448.9873.

(*E*)-(1-(4-Bromophenyl)-2-tosylprop-1-en-1-yl)(phenyl)selane (**6d**).^{15b} Following the general procedure A, **6d** was obtained as a white solid. (77% yield, 113.6 mg). mp: 144–145 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.55 (d, J = 7.0 Hz, 2H), 7.45–7.36 (m, 5H), 7.33 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 7.06 (d, J = 8.0 Hz, 2H), 6.16 (s, 1H), 2.38 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 155.4, 143.9, 138.6, 136.5, 133.6, 131.0, 130.2, 130.1, 129.4, 127.4, 126.5, 126.4, 123.7, 21.6. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{21}\text{H}_{17}\text{BrO}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 514.9190, found 514.9193.

(*E*)-4-(1-(Phenylselanyl)-2-tosylprop-1-en-1-yl)benzoxonitrile (**6e**). Following the general procedure A, **6e** was obtained as a white solid. (63% yield, 83.0 mg). mp: 128–129 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.62–7.49 (m, 4H), 7.48–7.42 (m, 1H), 7.41–7.33 (m, 4H), 7.32–7.25 (m, 2H), 7.19 (d, J = 7.6 Hz, 2H), 6.23 (s, 1H), 2.40 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 153.9, 144.3, 139.6, 138.4, 136.6, 131.5, 130.4, 130.3, 129.6, 129.2, 127.3, 126.9, 125.9, 118.3, 112.8, 21.6. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{22}\text{H}_{17}\text{NO}_2\text{SSe}$ ($[\text{M} + \text{H}]^+$), 440.0224, found 440.0228.

(*E*)-(1-(3-Chlorophenyl)-2-tosylprop-1-en-1-yl)(phenyl)selane (**6f**). Following the general procedure A, **6f** was obtained as a white solid. (79% yield, 106.2 mg). mp: 120–121 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, J = 7.2 Hz, 2H), 7.49–7.36 (m, 3H), 7.32 (d, J = 8.4 Hz, 2H), 7.24 (t, J = 8.0 Hz, 2H), 7.15 (d, J = 8.0 Hz, 3H), 6.94 (s, 1H), 6.20 (s, 1H), 2.40 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 155.0, 144.0, 138.5, 136.6, 136.2, 133.8, 130.3, 130.2, 129.2, 128.0,

127.4, 126.89, 126.86, 126.3, 21.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{21}\text{H}_{17}\text{ClO}_2\text{SSe}$ ($[\text{M} + \text{H}]^+$), 448.9887, found 448.9873.

(*E*)-(1-(3-Nitrophenyl)-2-tosylvinyl)(phenyl)selane (**6g**). Following the general procedure A, **6g** was obtained as a white solid. (42% yield, 57.8 mg). mp: 162–163 °C; ^1H NMR (400 MHz, CDCl_3) δ 8.16 (d, J = 8.0 Hz, 1H), 7.80 (s, 1H), 7.63 (d, J = 7.6 Hz, 1H), 7.57 (d, J = 7.0 Hz, 2H), 7.51 (t, J = 8.0 Hz, 1H), 7.46 (t, J = 7.2 Hz, 1H), 7.39 (t, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 6.28 (s, 1H), 2.38 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 153.4, 147.5, 144.4, 138.3, 136.6, 136.4, 134.8, 130.5, 130.3, 129.6, 129.0, 127.5, 127.3, 125.9, 123.8, 123.0, 21.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{21}\text{H}_{17}\text{NO}_4\text{SSe}$ ($[\text{M} + \text{H}]^+$), 460.0123, found 460.0128.

(*E*)-(1-(2-Chlorophenyl)-2-tosylvinyl)(phenyl)selane (**6h**). Following the general procedure A, **6h** was obtained as a white solid. (68% yield, 91.4 mg). mp: 124–125 °C; ^1H NMR (400 MHz, cdCl_3) δ 7.57–7.52 (m, 2H), 7.47–7.31 (m, 5H), 7.25–7.22 (m, 2H), 7.17–7.11 (m, 4H), 6.18 (s, 1H), 2.38 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 154.9, 143.9, 138.4, 136.5, 136.2, 133.7, 130.2, 130.2, 129.3, 129.1, 127.9, 127.4, 126.8, 126.8, 126.2, 21.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{21}\text{H}_{17}\text{ClO}_2\text{SSe}$ ($[\text{M} + \text{H}]^+$), 448.9881, found 448.9878.

(*E*)-Methyl 2-(1-(Phenylselanyl)-2-tosylvinyl)benzoate (**6i**). Following the general procedure A, **6i** was obtained as a yellow oil. (86% yield, 121.8 mg). ^1H NMR (400 MHz, CDCl_3) δ 7.92 (d, J = 7.6, 1H), 7.59–7.53 (m, 2H), 7.46–7.35 (m, 3H), 7.34–7.27 (m, 4H), 7.12 (d, J = 8.8 Hz, 3H), 6.24 (s, 1H), 3.75 (s, 3H), 2.35 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 165.4, 156.2, 143.6, 138.4, 136.6, 135.9, 131.5, 130.4, 130.0, 129.8, 129.8, 129.2, 128.9, 128.3, 127.5, 126.7, 124.8, 51.8, 21.4. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{23}\text{H}_{20}\text{O}_4\text{SSe}$ ($[\text{M} + \text{H}]^+$), 473.0326, found 473.0328.

(*E*)-Phenyl(1-(*p*-tolyl)-2-tosylvinyl)selane (**6j**).^{15b} Following the general procedure A, **6j** was obtained as a white solid. (94% yield, 120.7 mg). mp: 162–163 °C; ^1H NMR (600 MHz, CDCl_3) δ 7.574 (d, J = 6.6 Hz, 2H), 7.46–7.41 (m, 1H), 7.38 (t, J = 7.2 Hz, 2H), 7.33 (d, J = 7.8 Hz, 2H), 7.14–7.06 (m, 6H), 6.10 (s, 1H), 2.37 (s, 3H), 2.36 (s, 3H). ^{13}C NMR (151 MHz, CDCl_3) δ 157.4, 143.5, 139.5, 139.0, 136.5, 131.7, 130.1, 130.0, 129.2, 128.5, 128.4, 127.4, 127.1, 125.4, 21.5, 21.4. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{22}\text{H}_{20}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 451.0277, found 451.0271.

(*E*)-(1-(4-Ethylphenyl)-2-tosylprop-1-en-1-yl)(phenyl)selane (**6k**). Following the general procedure A, **6k** was obtained as a white solid. (88% yield, 116.7 mg). mp: 91–92 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, J = 6.4, 2H), 7.47–7.35 (m, 3H), 7.29 (d, J = 8.4 Hz, 1H), 7.17–7.03 (m, 6H), 6.12 (s, 1H), 2.64 (q, J = 8.0 Hz, 2H), 2.35 (s, 3H), 1.24 (t, J = 7.6 Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 157.4, 145.7, 143.4, 138.8, 136.5, 131.8, 130.1, 130.0, 129.1, 128.5, 127.4, 127.3, 127.0, 125.6, 28.7, 21.5, 15.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{23}\text{H}_{22}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 465.0406, found 465.0398.

(*E*)-(1-(4-*tert*-Butylphenyl)-2-tosylprop-1-en-1-yl)(phenyl)selane (**6l**). Following the general procedure A, **6l** was obtained as a white solid. (85% yield, 119.9 mg). mp: 121–122 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, J = 6.8 Hz, 2H), 7.46–7.34 (m, 3H), 7.26–7.20 (m, 4H), 7.08 (d, J = 8.0 Hz, 2H), 7.02 (d, J = 8.0 Hz, 2H), 6.13 (s, 1H), 2.32 (s, 3H), 1.30 (s, 9H). ^{13}C NMR (126 MHz, CDCl_3) δ 157.3, 152.5, 143.2, 138.7, 136.6, 131.5, 130.2, 130.0, 129.0, 128.2, 127.5, 126.9, 125.9, 124.7, 34.7, 31.2, 21.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{25}\text{H}_{26}\text{O}_2\text{SSe}$ ($[\text{M} + \text{H}]^+$), 471.0898, found 471.0892.

(*E*)-Phenyl(1-(*m*-tolyl)-2-tosylvinyl)selane (**6m**). Following the general procedure A, **6m** was obtained as a white solid. (86% yield, 110.4 mg). mp: 109–110 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.62–7.56 (m, 2H), 7.47–7.35 (m, 3H), 7.32–7.26 (m, 2H), 7.17 (t, J = 7.6 Hz, 1H), 7.10 (t, J = 7.2 Hz, 3H), 7.03 (d, J = 7.2 Hz, 1H), 6.86 (s, 1H), 6.13 (s, 1H), 2.36 (s, 3H), 2.26 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 157.4, 143.4, 138.9, 137.5, 136.6, 134.43, 130.2, 130.1, 130.0, 129.1, 128.7, 127.8, 127.5, 125.7, 125.6, 21.5, 21.2. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{22}\text{H}_{20}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 451.0251, found 451.0242.

(*E*)-Phenyl(4-phenyl-1-tosylbut-1-en-2-yl)selane (**6n**). Following the general procedure A, **6n** was obtained as a white solid. (82% yield, 108.7 mg). mp: 90–91 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.65 (d, J = 8.0 Hz, 2H), 7.54 (d, J = 7.0 Hz, 2H), 7.44 (t, J = 7.5 Hz, 1H),

7.38 (t, $J = 7.5$ Hz, 2H), 7.33–7.24 (m, 4H), 7.22 (d, $J = 7.5$ Hz, 3H), 5.94 (s, 1H), 3.11 (q, $J = 5.0$ Hz, 2H), 2.97–2.89 (m, 2H), 2.41 (s, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 159.1, 144.0, 139.2, 136.6, 136.5, 130.0, 129.9, 129.8, 129.2, 128.4, 127.1, 127.0, 126.1, 124.9, 38.3, 21.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{23}\text{H}_{22}\text{O}_2\text{SSe}$ ($[\text{M} + \text{H}]^+$), 443.0586, found 443.0579.

(*E*)-Phenyl(1-tosylhex-1-en-2-yl)selane (**6o**). Following the general procedure A, **6o** was obtained as a white solid. (85% yield, 100.5 mg). mp: 68–69 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.67 (d, $J = 8.0$ Hz, 2H), 7.54–7.49 (m, 2H), 7.45–7.33 (m, 3H), 7.28 (d, $J = 8.4$ Hz, 2H), 5.85 (s, 1H), 2.83 (t, $J = 8.0$ Hz, 2H), 2.41 (s, 3H), 1.60–1.49 (m, 2H), 1.42–1.29 (m, 2H), 0.89 (t, $J = 7.2$ Hz, 3H). ^{13}C NMR (126 MHz, CDCl_3) δ 161.4, 143.8, 139.6, 136.7, 130.0, 129.9, 129.7, 126.9, 125.9, 123.7, 33.0, 32.1, 22.5, 21.5, 13.8. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{19}\text{H}_{22}\text{O}_2\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 417.0403, found 417.0398.

(*E*)-(6-Chloro-1-tosylhex-1-en-2-yl)(phenyl)selane (**6p**). Following the general procedure A, **6p** was obtained as a white solid. (88% yield, 113.0 mg). mp: 90–91 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.67 (d, $J = 8.4$ Hz, 2H), 7.55–7.50 (m, 2H), 7.44 (t, $J = 7.2$ Hz, 1H), 7.38 (t, $J = 7.2$ Hz, 2H), 7.30 (d, $J = 8.0$ Hz, 2H), 5.90 (s, 1H), 3.54 (t, $J = 6.4$ Hz, 2H), 2.88 (t, $J = 7.6$ Hz, 2H), 2.43 (s, 3H), 1.87–1.68 (m, 4H). ^{13}C NMR (151 MHz, CDCl_3) δ 160.0, 144.01, 133.99, 139.5, 136.7, 130.1, 130.0, 129.8, 126.9, 125.8, 124.4, 44.5, 32.2, 32.0, 27.3, 21.6. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{19}\text{H}_{21}\text{ClO}_2\text{SSe}$ ($[\text{M} + \text{H}]^+$), 429.0195, found 429.0191.

(*E*)-1-(1-(Phenylselanyl)-2-tosylvinyl)cyclohexanol (**6q**). Following the general procedure A, **6q** was obtained as a white solid. (73% yield, 95.5 mg). mp: 56–58 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.62 (d, $J = 8.4$ Hz, 2H), 7.46 (d, $J = 7.6$ Hz, 2H), 7.38 (t, $J = 7.2$ Hz, 1H), 7.31 (t, $J = 7.6$ Hz, 2H), 7.28–7.22 (m, 2H), 5.54 (s, 1H), 4.83 (s, 1H), 2.41 (s, 3H), 2.09–1.90 (m, 4H), 1.87–1.68 (m, 3H), 1.66–1.55 (m, 2H). ^{13}C NMR (151 MHz, CDCl_3) δ 169.6, 143.9, 138.5, 136.6, 130.1, 129.8, 129.6, 127.6, 126.9, 122.7, 76.3, 36.2, 25.0, 21.5, 21.3. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{21}\text{H}_{24}\text{O}_3\text{SSe}$ ($[\text{M} + \text{Na}]^+$), 459.0508, found 459.0504.

(*E*)-Trimethyl(1-(phenylselanyl)-2-tosylvinyl)silane (**6r**). Following the general procedure A, **6r** was obtained as a white solid. (64% yield, 78.7 mg). mp: 81–82 °C; ^1H NMR (400 MHz, CDCl_3) δ 7.56 (d, $J = 8.4$ Hz, 2H), 7.45–7.30 (m, 5H), 7.24 (d, $J = 8.4$ Hz, 2H), 6.04 (s, 1H), 2.40 (s, 3H), 0.49 (s, 9H). ^{13}C NMR (151 MHz, CDCl_3) δ 159.9, 143.7, 138.5, 136.8, 131.6, 130.1, 129.8, 129.7, 126.9, 126.7, 21.5, 0.5. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{18}\text{H}_{22}\text{O}_2\text{SSeSi}$ ($[\text{M} + \text{Na}]^+$), 433.0174, found 433.0167.

(*E*)-Methyl(1-phenyl-2-tosylvinyl)selane (**6s**). Following the general procedure A, **6s** was obtained as a yellow oil. (35% yield, 43.5 mg). ^1H NMR (600 MHz, CDCl_3) δ 7.39 (d, $J = 8.4$ Hz, 2H), 7.34 (t, $J = 7.2$ Hz, 1H), 7.28 (t, $J = 7.8$ Hz, 2H), 7.13 (d, $J = 7.8$ Hz, 4H), 6.44 (s, 1H), 2.38 (s, 3H), 2.15 (s, 3H). ^{13}C NMR (150 MHz, CDCl_3) δ 156.1, 143.6, 138.9, 135.2, 129.3, 129.2, 128.2, 127.8, 127.5, 124.8, 21.5, 8.6. HRMS (ESI-TOF) (m/z): Calcd for $\text{C}_{16}\text{H}_{16}\text{O}_2\text{SSe}$ ($[\text{M} + \text{K}]^+$), 390.9668, found 390.9643.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b03049.

Crystallographic data for **4a** (CIF)

Crystallographic data for **6a** (CIF)

Crystallographic data for **6p** (CIF)

Spectral data for new compounds (PDF)

AUTHOR INFORMATION

Corresponding Authors

*E-mail: liy078@nenu.edu.cn (Y.L.).

*E-mail: zhangq651@nenu.edu.cn (Q.Z.).

ORCID

Yan Li: 0000-0003-2083-6991

Notes

The authors declare no competing financial interest.

[†]These authors are different persons.

ACKNOWLEDGMENTS

We acknowledge the financial support for this work from the National NSF of China (21172033, 21372041, and 21302017), Changbai Mountain Scholarship Program, and the Fundamental Research Funds for the Central Universities (2412016KJ006).

REFERENCES

- (1) (a) Ettari, R.; Nizi, E.; Di Francesco, M. E.; Dude, M.-A.; Pradel, G.; Vicik, R.; Schirmeister, T.; Micale, N.; Grasso, S.; Zappala, M. *J. Med. Chem.* **2008**, *51*, 988–996. (b) Ni, L.; Zheng, X. S.; Somers, P. K.; Hoong, L. K.; Hill, R. R.; Marino, E. M.; Suen, K.-L.; Saxena, U.; Meng, C. Q. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 745–748. (c) Forristal, I. J. *J. Sulfur Chem.* **2005**, *26*, 163–195. (d) Wang, G.; Mahesh, U.; Chen, G. Y. J.; Yao, S.-Q. *Org. Lett.* **2003**, *5*, 737–740. (e) Ni, L.; Zheng, X. S.; Somers, P. K.; Hoong, L. K.; Hill, R. R.; Marino, E. M.; Suen, K.-L.; Saxena, U.; Meng, C. Q. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 745–748.
- (2) (a) Pandey, G.; Tiwari, K. N.; Puranik, V. G. *Org. Lett.* **2008**, *10*, 3611–3614. (b) Oh, K. *Org. Lett.* **2007**, *9*, 2973–2975. (c) Desrosiers, J. N.; Charette, A. B. *Angew. Chem., Int. Ed.* **2007**, *46*, 5955–5957. (d) Noshi, M. N.; El-Awa, A.; Torres, E.; Fuchs, P. L. *J. Am. Chem. Soc.* **2007**, *129*, 11242–11247. (e) Mu, L.; Drandarov, K.; Bisson, W. H.; Schibig, A.; Wirz, C.; Schubiger, P. A.; Westera, G. *Eur. J. Med. Chem.* **2006**, *41*, 640–650. (f) Hof, F.; Schutz, A.; Fah, C.; Meyer, S.; Bur, D.; Liu, J.; Goldberg, D. E.; Diederich, E. *Angew. Chem., Int. Ed.* **2006**, *45*, 2138–2141. (g) Wardrop, D. J.; Fritz, J. *Org. Lett.* **2006**, *8*, 3659–3662.
- (3) A recent review; see: Fang, Y.; Luo, Z.; Xu, X. *RSC Adv.* **2016**, *6*, 59661–59676.
- (4) (a) Kirihara, M.; Yamamoto, J.; Noguchi, T.; Hirai, Y. *Tetrahedron Lett.* **2009**, *50*, 1180–1183. (b) Huang, X.; Duan, D.-H.; Zheng, W.-X. *J. Org. Chem.* **2003**, *68*, 1958–1963.
- (5) (a) Balasubramanian, M.; Baliah, V. *J. Am. Chem. Soc.* **1954**, *0*, 1844–1847. (b) Chodroff, S.; Whitmore, W. F. *J. Am. Chem. Soc.* **1950**, *72*, 1073–1076. (c) Happer, D. A. R.; Steenson, B. E. *Synthesis* **1980**, 1980, 806–807.
- (6) van Steenis, J. H.; van Es, J. J. G. S.; van der Gen, A. *Eur. J. Org. Chem.* **2000**, *2000*, 2787–2793.
- (7) (a) Back, T. G.; Collins, S. *Tetrahedron Lett.* **1980**, *21*, 2215–2218. (b) Back, T. G.; Collins, S. *J. Org. Chem.* **1981**, *46*, 3249–3256. (c) Ganczar, R. A.; Kice, J. L. *Tetrahedron Lett.* **1980**, *21*, 4155–4158. (d) Asscher, M.; Vofsi, D. *J. Chem. Soc.* **1964**, 4962–4971. (e) Sinnreich, J.; Asscher, M. *J. Chem. Soc., Perkin Trans. 1* **1972**, 1543–1545. (f) Hopkins, P. B.; Fuchs, P. L. *J. Org. Chem.* **1978**, *43*, 1208–1217.
- (8) (a) Nie, G.; Deng, X.; Lei, X.; Hu, Q.; Chen, Y. *RSC Adv.* **2016**, *6*, 75277–75281. (b) Zhang, N.; Yang, D.; Wei, W.; Yuan, L.; Cao, Y.; Wang, H. *RSC Adv.* **2015**, *5*, 37013–37017. (c) Katrun, P.; Chiampanichayakul, S.; Korworapan, K.; Pohmakotr, M.; Reutrakul, V.; Jaipetch, T.; Kuhakarn, C. *Eur. J. Org. Chem.* **2010**, *2010*, 5633–5641. (d) Nair, V.; Augustine, A.; Suja, T. D. *Synthesis* **2002**, 2259–2265. (e) Taniguchi, N. *Synlett* **2011**, *2011*, 1308–1312. (f) Taniguchi, N. *Synlett* **2012**, *23*, 1245–1249. (g) Li, X.; Xu, Y.; Wu, W.; Jiang, C.; Qi, C.; Jiang, H. *Chem. - Eur. J.* **2014**, *20*, 7911–7915.
- (9) (a) Wan, J.-P.; Hu, D.; Bai, F.; Wei, L.; Liu, Y. *RSC Adv.* **2016**, *6*, 73132–73135. (b) Wei, W.; Wen, J.; Yang, D.; Jing, H.; You, J.; Wang, H. *RSC Adv.* **2015**, *5*, 4416–4419. (c) Wei, W.; Li, J.; Yang, D.; Wen, J.; Jiao, Y.; You, J.; Wang, H. *Org. Biomol. Chem.* **2014**, *12*, 1861–1864 and references cited therein.
- (10) (a) Lai, C.; Xi, C.; Jiang, Y.; Hua, R. *Tetrahedron Lett.* **2005**, *46*, 513–515. (b) Lu, Q.; Zhang, J.; Zhao, G.; Qi, Y.; Wang, H.; Lei, A. *J. Am. Chem. Soc.* **2013**, *135*, 11481–11484.

(11) Chen, F.; Meng, Q.; Han, S.-Q.; Han, B. *Org. Lett.* **2016**, *18*, 3330–3333.

(12) (a) Wen, J.; Wei, W.; Xue, S.; Yang, D.; Lou, Y.; Gao, C.; Wang, H. *J. Org. Chem.* **2015**, *80*, 4966–4972. (b) Senadi, G. C.; Guo, B.-C.; Hu, W.-P.; Wang, J.-J. *Chem. Commun.* **2016**, *52*, 11410–11413. (c) Hao, W.-J.; Du, Y.; Wang, D.; Jiang, B.; Gao, Q.; Tu, S.-J.; Li, G. *Org. Lett.* **2016**, *18*, 1884–1887.

(13) Mugesh, G.; du Mont, W.-W.; Sies, H. *Chem. Rev.* **2001**, *101*, 2125–2180.

(14) Recent reviews; see: (a) Beletskaya, I. P.; Ananikov, V. P. *Chem. Rev.* **2011**, *111*, 1596–1636. (b) Orlov, N. V. *ChemistryOpen* **2015**, *4*, 682–697.

(15) (a) Back, T. G.; Collins, S. *Tetrahedron Lett.* **1981**, *22*, 5111–5114. (b) Miura, T.; Kobayashi, M. *J. Chem. Soc., Chem. Commun.* **1982**, 438–439. (c) Back, T. G.; Collins, S.; Kerr, R. G. *J. Org. Chem.* **1983**, *48*, 3077–3084. (d) Back, T. G.; Collins, S.; Gokhale, U.; Law, K.-W. *J. Org. Chem.* **1983**, *48*, 4776–4779. (e) Back, T. G.; Collins, S.; Krishna, M. V.; Law, K.-W. *J. Org. Chem.* **1987**, *52*, 4258–4264. (f) Back, T. G.; Krishna, M. V.; Muralidharan, K. R. *J. Org. Chem.* **1989**, *54*, 4146–4153. (g) Back, T. G.; Nakajima, K. *J. Org. Chem.* **1998**, *63*, 6566–6571.

(16) (a) Gancarz, R. A.; Kice, J. L. *Tetrahedron Lett.* **1980**, *21*, 1697–1700. (b) Back, T. G.; Collins, S.; Krishna, M. V. *Can. J. Chem.* **1987**, *65*, 38–42. (c) Wang, L.; Huang, X. *Synth. Commun.* **1993**, *23*, 2817–2820. (d) Chen, D.-W.; Chen, Z.-C. *Tetrahedron Lett.* **1994**, *35*, 7637–7638.

(17) Huang, X.; Xu, Q.; Liang, C.-G.; He, Q.-W. *Synth. Commun.* **2002**, *32*, 1243–1249.

(18) (a) Zheng, G.; Li, Y.; Han, J.; Xiong, T.; Zhang, Q. *Nat. Commun.* **2015**, *6*, 7011. (b) Sun, J.; Zheng, G.; Xiong, T.; Zhang, Q.; Zhao, J.; Li, Y.; Zhang, Q. *ACS Catal.* **2016**, *6*, 3674–3678.

(19) (a) Ni, Z.; Zhang, Q.; Xiong, T.; Zheng, Y.; Li, Y.; Zhang, H.; Zhang, J.; Liu, Q. *Angew. Chem., Int. Ed.* **2012**, *51*, 1244–1247. (b) Zhang, Q.; Lv, Y.; Li, Y.; Xiong, T.; Zhang, Q. *Acta Chim. Sin.* **2014**, *72*, 1139–1143. (c) Sun, K.; Li, Y.; Zhang, Q. *Sci. China: Chem.* **2015**, *58*, 1354–1358. (d) Zhang, G.; Xiong, T.; Wang, Z.; Xu, G.; Wang, X.; Zhang, Q. *Angew. Chem., Int. Ed.* **2015**, *54*, 12649–12653. (e) Li, Y.; Zhou, X.; Zheng, G.; Zhang, Q. *Beilstein J. Org. Chem.* **2015**, *11*, 2721–2726.

(20) For the crystal structure of **4a**, see CCDC 1517579, **6a** see CCDC 1517580, and **6p** see 1517581. For the corresponding figures and tables, see Figures S1, S2, S3 and Tables S1, S2, S3 in the [Supporting Information](#).

(21) (a) Zhang, M.; Xie, P.; Zhao, W.; Niu, B.; Wu, W.; Bian, Z.; Pittman, C. U., Jr.; Zhou, A. *J. Org. Chem.* **2015**, *80*, 4176–4183. (b) Taniguchi, T.; Idota, A.; Ishibashi, H. *Org. Biomol. Chem.* **2011**, *9*, 3151–3153. (c) Li, X.; Xu, X.; Hu, P.; Xiao, X.; Zhou, C. *J. Org. Chem.* **2013**, *78*, 7343. (d) Wei, W.; Wen, J.; Yang, D.; Guo, M.; Wang, Y.; You, J.; Wang, H. *Chem. Commun.* **2015**, *51*, 768–778. (e) Li, X.; Xu, X.; Tang, Y. *Org. Biomol. Chem.* **2013**, *11*, 1739–1742. (f) Li, X.; Xu, X.; Zhou, C. *Chem. Commun.* **2012**, *48*, 12240–11242. (g) Chen, Z.; Liu, S.; Hao, W.; Xu, G.; Wu, S.; Miao, J.; Jiang, B.; Wang, S.; Tu, S.; Li, G. *Chem. Sci.* **2015**, *6*, 6654–6658. (h) Barton, D. H.R.; Csiba, M. A.; Jaszberenyi, J. Cs. *Tetrahedron Lett.* **1994**, *35*, 2869–2872.

(22) (a) Taniguchi, T.; Sugiura, Y.; Zaimoku, H.; Ishibashi, H. *Angew. Chem., Int. Ed.* **2010**, *49*, 10154–10355. (b) Taniguchi, T.; Zaimoku, H.; Ishibashi, H. *Chem. - Eur. J.* **2011**, *17*, 4307–4312. (c) Taniguchi, T.; Idota, A.; Ishibashi, H. *Org. Biomol. Chem.* **2011**, *9*, 3151–3153. (d) Wei, W.; Liu, C.; Yang, D.; Wen, J.; You, J.; Suo, Y.; Wang, H. *Chem. Commun.* **2013**, *49*, 10239–10241.